Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Multilaboratory approach to preclinical evaluation of vaccine immunogens for placental malaria

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Fried, M, Avril, M, Chaturvedi, R, Fernandez, P, Lograsso, J, Narum, D, Nielsen, MA, Oleinikov, AV, Resende, M, Salanti, A, Saveria, T, Williamson, K, Dicko, A, Scherf, A, Smith, JD, Theander, TG & Duffy, PE 2013, 'Multilaboratory approach to preclinical evaluation of vaccine immunogens for placental malaria', Infection and Immunity, vol. 81, no. 2, pp. 487-95. https://doi.org/10.1128/IAI.01106-12

APA

Fried, M., Avril, M., Chaturvedi, R., Fernandez, P., Lograsso, J., Narum, D., Nielsen, M. A., Oleinikov, A. V., Resende, M., Salanti, A., Saveria, T., Williamson, K., Dicko, A., Scherf, A., Smith, J. D., Theander, T. G., & Duffy, P. E. (2013). Multilaboratory approach to preclinical evaluation of vaccine immunogens for placental malaria. Infection and Immunity, 81(2), 487-95. https://doi.org/10.1128/IAI.01106-12

CBE

Fried M, Avril M, Chaturvedi R, Fernandez P, Lograsso J, Narum D, Nielsen MA, Oleinikov AV, Resende M, Salanti A, Saveria T, Williamson K, Dicko A, Scherf A, Smith JD, Theander TG, Duffy PE. 2013. Multilaboratory approach to preclinical evaluation of vaccine immunogens for placental malaria. Infection and Immunity. 81(2):487-95. https://doi.org/10.1128/IAI.01106-12

MLA

Vancouver

Author

Fried, Michal ; Avril, Marion ; Chaturvedi, Richa ; Fernandez, Pablo ; Lograsso, Joseph ; Narum, David ; Nielsen, Morten A ; Oleinikov, Andrew V ; Resende, Mafalda ; Salanti, Ali ; Saveria, Tracy ; Williamson, Kathryn ; Dicko, Alassane ; Scherf, Artur ; Smith, Joseph D ; Theander, Thor G ; Duffy, Patrick E. / Multilaboratory approach to preclinical evaluation of vaccine immunogens for placental malaria. In: Infection and Immunity. 2013 ; Vol. 81, No. 2. pp. 487-95.

Bibtex

@article{b5fb8bab56d2405088b36b6a646de527,
title = "Multilaboratory approach to preclinical evaluation of vaccine immunogens for placental malaria",
abstract = "Pregnancy malaria is caused by Plasmodium falciparum-infected erythrocytes that adhere to the placental receptor chondroitin sulfate A (CSA) and sequester in the placenta; women become resistant to pregnancy malaria as they acquire antiadhesion antibodies that target surface proteins of placental parasites. VAR2CSA, a member of the P. falciparum EMP1 variant surface antigen family, is the leading candidate for a pregnancy malaria vaccine. Because VAR2CSA is a high-molecular-weight protein, a vaccine based on the full-length protein may not be feasible. An alternative approach has been to develop a vaccine targeting individual Duffy binding-like (DBL) domains. In this study, a consortium of laboratories under the Pregnancy Malaria Initiative compared the functional activity of antiadhesion antibodies elicited by different VAR2CSA domains and variants produced in prokaryotic and eukaryotic expression systems. Antisera were initially tested against laboratory lines of maternal parasites, and the most promising reagents were evaluated in the field against fresh placental parasite samples. Recombinant proteins expressed in Escherichia coli elicited antibody levels similar to those expressed in eukaryotic systems, as did the two allelic forms of the DBL4 and DBL5 domains. The procedures developed for this head-to-head comparison will be useful for future evaluation and down-selection of malaria vaccine immunogens.",
keywords = "Animals, Antibodies, Protozoan, Antigens, Protozoan, Chondroitin Sulfates, Cohort Studies, Female, Humans, Immune Sera, Immunoglobulin G, Longitudinal Studies, Malaria Vaccines, Malaria, Falciparum, Placenta, Plasmodium falciparum, Pregnancy, Pregnancy Complications, Parasitic, Rats, Recombinant Proteins",
author = "Michal Fried and Marion Avril and Richa Chaturvedi and Pablo Fernandez and Joseph Lograsso and David Narum and Nielsen, {Morten A} and Oleinikov, {Andrew V} and Mafalda Resende and Ali Salanti and Tracy Saveria and Kathryn Williamson and Alassane Dicko and Artur Scherf and Smith, {Joseph D} and Theander, {Thor G} and Duffy, {Patrick E}",
year = "2013",
month = feb,
doi = "10.1128/IAI.01106-12",
language = "English",
volume = "81",
pages = "487--95",
journal = "Infection and Immunity",
issn = "0019-9567",
publisher = "American Society for Microbiology",
number = "2",

}

RIS

TY - JOUR

T1 - Multilaboratory approach to preclinical evaluation of vaccine immunogens for placental malaria

AU - Fried, Michal

AU - Avril, Marion

AU - Chaturvedi, Richa

AU - Fernandez, Pablo

AU - Lograsso, Joseph

AU - Narum, David

AU - Nielsen, Morten A

AU - Oleinikov, Andrew V

AU - Resende, Mafalda

AU - Salanti, Ali

AU - Saveria, Tracy

AU - Williamson, Kathryn

AU - Dicko, Alassane

AU - Scherf, Artur

AU - Smith, Joseph D

AU - Theander, Thor G

AU - Duffy, Patrick E

PY - 2013/2

Y1 - 2013/2

N2 - Pregnancy malaria is caused by Plasmodium falciparum-infected erythrocytes that adhere to the placental receptor chondroitin sulfate A (CSA) and sequester in the placenta; women become resistant to pregnancy malaria as they acquire antiadhesion antibodies that target surface proteins of placental parasites. VAR2CSA, a member of the P. falciparum EMP1 variant surface antigen family, is the leading candidate for a pregnancy malaria vaccine. Because VAR2CSA is a high-molecular-weight protein, a vaccine based on the full-length protein may not be feasible. An alternative approach has been to develop a vaccine targeting individual Duffy binding-like (DBL) domains. In this study, a consortium of laboratories under the Pregnancy Malaria Initiative compared the functional activity of antiadhesion antibodies elicited by different VAR2CSA domains and variants produced in prokaryotic and eukaryotic expression systems. Antisera were initially tested against laboratory lines of maternal parasites, and the most promising reagents were evaluated in the field against fresh placental parasite samples. Recombinant proteins expressed in Escherichia coli elicited antibody levels similar to those expressed in eukaryotic systems, as did the two allelic forms of the DBL4 and DBL5 domains. The procedures developed for this head-to-head comparison will be useful for future evaluation and down-selection of malaria vaccine immunogens.

AB - Pregnancy malaria is caused by Plasmodium falciparum-infected erythrocytes that adhere to the placental receptor chondroitin sulfate A (CSA) and sequester in the placenta; women become resistant to pregnancy malaria as they acquire antiadhesion antibodies that target surface proteins of placental parasites. VAR2CSA, a member of the P. falciparum EMP1 variant surface antigen family, is the leading candidate for a pregnancy malaria vaccine. Because VAR2CSA is a high-molecular-weight protein, a vaccine based on the full-length protein may not be feasible. An alternative approach has been to develop a vaccine targeting individual Duffy binding-like (DBL) domains. In this study, a consortium of laboratories under the Pregnancy Malaria Initiative compared the functional activity of antiadhesion antibodies elicited by different VAR2CSA domains and variants produced in prokaryotic and eukaryotic expression systems. Antisera were initially tested against laboratory lines of maternal parasites, and the most promising reagents were evaluated in the field against fresh placental parasite samples. Recombinant proteins expressed in Escherichia coli elicited antibody levels similar to those expressed in eukaryotic systems, as did the two allelic forms of the DBL4 and DBL5 domains. The procedures developed for this head-to-head comparison will be useful for future evaluation and down-selection of malaria vaccine immunogens.

KW - Animals

KW - Antibodies, Protozoan

KW - Antigens, Protozoan

KW - Chondroitin Sulfates

KW - Cohort Studies

KW - Female

KW - Humans

KW - Immune Sera

KW - Immunoglobulin G

KW - Longitudinal Studies

KW - Malaria Vaccines

KW - Malaria, Falciparum

KW - Placenta

KW - Plasmodium falciparum

KW - Pregnancy

KW - Pregnancy Complications, Parasitic

KW - Rats

KW - Recombinant Proteins

U2 - 10.1128/IAI.01106-12

DO - 10.1128/IAI.01106-12

M3 - Journal article

C2 - 23208604

VL - 81

SP - 487

EP - 495

JO - Infection and Immunity

JF - Infection and Immunity

SN - 0019-9567

IS - 2

ER -

ID: 41634087